Summary Regenerative medicine could potentially cure diseases and may replace palliative treatments for chronic diseases.Stem cells in particular have been studied for their regenerative properties: their potential to repair or replace damaged or diseased human cells or tissues to restore normal function.
Stem cells are able to develop into different cell types in the body during early the early stages of life and growth. They have a role in repairing many types of damaged tissue.
The FDA has put out a comprehensive policy framework for the development and oversight of regenerative medicine products through the 21st Century Cures Act, legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) to patients who need them faster and more efficiently.
Studies of stem cell therapies targeting cardiovascular indications such as heart failure (HF), myocardial infarction (MI), cardiomyopathy (CM), and left ventricular dysfunction (LVD) aim to demonstrate that stem cells injected into the circulation or directly into the injured heart tissue improve cardiac function and/or induce the formation of new capillaries.
The majority of CVMD pipeline candidates are in preclinical development, with ~73% of CVMD stem cell pipeline therapies specifically targeting cardiovascular indications. Representative stem cell types that are being investigated in clinical trials towards CV indications include mesenchymal precursor, ischemia-tolerant mesenchymal, myoblast, immunomodulatory progenitor, and heart-derived stem cells.
Currently, there is an absence of big pharma investment in cardiovascular stem cell therapy clinical development, with the majority of the R&D efforts in this space being undertaken by small biotech companies.
The report "Stem Cell Therapies in CVMD", provides an assessment of the pipeline, clinical, and commercial landscape of stem cell therapies in CVMD. Overall, it is expected that new stem cell therapy approvals will drive CVMD market growth from 2018-2025.
Scope Components of the slide deck include - - Overview of CVMD and Stem Cells: epidemiology and regulatory oversight - Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type - Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors - Market Access: considerations for reimbursement, pricing, and unmet needs - Market Outlook: competitive assessment and key market events (2018-2025).
Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global CVMD stem cell therapy market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CVMD stem cell therapy market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Our reports have been used by over 10K customers, including:
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
Insulin Like Growth Factor I - Pipeline Review, H2 2020
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived...
Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs
The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate...
The global in vitro toxicology testing market is projected to grow at a CAGR of 10.3%.
The in vitro toxicology testing market is expected to reach USD 14.9 billion by 2025 from an estimated USD 9.1 billion in 2020, at a CAGR of 10.3%. The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect...
State of the Biopharmaceutical Industry 2021
2021 promises to be a year of continued innovation and change in the biopharmaceutical industry. While the biopharmaceutical sector has traditionally been labelled as highly resistant to recessions, COVID-19 has presented and will continue to...
The increasing number of lyophilized drugs is projected to drive the dual chamber syringes market.
The global dual chamber syringes market size is projected to grow from USD 131 million in 2020 to USD 182 million by 2025, at a compound annual growth rate (CAGR) of 6.8% between 2020 and 2025. The global dual chamber syringes industry has...
Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H1 2020
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 46 molecules. Out of which approximately...
The global biopharmaceuticals market is found witnessing a CAGR of 7.32%. The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. Also, the huge demand of biopharmaceutical is facilitated by an accelerating focus in research and related investment. The...
Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020
According to the recently published report ’Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020’; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 22.214.171.124) pipeline Target constitutes close to 34 molecules. Out of which...
Insulin Like Growth Factor I - Pipeline Review, H1 2020
According to the recently published report ’Insulin Like Growth Factor I – Pipeline Review, H1 2020’; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules....
Prescription Drug Sales
Cause-Specific Mortality Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.